Amarin Corporation plc (NASDAQ: AMRN) shares are plunging after it said it would continue suspending 2022 revenue guidance and Q1 earnings came short of expectations.
Amarin Corp (NASDAQ:AMRN) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.02) by 200 percent. The company reported quarterly sales of $94.60 million which missed the
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.